Skip to Main Content

Author Details

Daniel J DeAngelo
Dana-Farber Cancer Institute
1989
293
77
PMIDPaper TitleJournal TitlePublished Year
37389830Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.Blood Adv2024
38086008CML and the WHO: Why?J Clin Oncol2024
37560812Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.Haematologica2024
37839675Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow.Mod Pathol2024
38052038Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.Blood Adv2024
37683132Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing.JCO Oncol Pract2024
36287540Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.Leuk Lymphoma2023
37597693Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma.Ann Allergy Asthma Immunol2023
37712875A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.Cancer Res Commun2023
37483562Prediction of risk for myeloid malignancy in clonal hematopoiesis.NEJM Evid2023
37648261Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.J Immunother Cancer2023
36949155Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.Leukemia2023
37451200Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.Leuk Res2023
37432068Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.Blood Adv2023
37163357FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged â¿¥60 years.Blood Adv2023
36655338Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial.Cancer2023
36579444A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.Haematologica2023
36805300Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Blood Rev2023
36577290Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.Leuk Res2023
36508268Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia.Blood Adv2023
36534523Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates.Clin Cancer Res2023
36727397Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.Haematologica2023
36332187Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.Blood2023
34543383Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.Blood2022
35643855Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.Clin Lymphoma Myeloma Leuk2022
35640224Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.Blood Adv2022
35790816Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.Leukemia2022
35696629Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.J Clin Oncol2022
36494725Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.J Hematol Oncol2022
36453519Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.Haematologica2022
36108424Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.Leuk Res2022
36054756Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.Am J Hematol2022
35877999Avapritinib for advanced systemic mastocytosis.Blood2022
34921959Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.Exp Hematol2022
35289704Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.Leuk Lymphoma2022
35317837Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.J Hematol Oncol2022
34981142Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.Ann Hematol2022
35312041Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia.Br J Haematol2022
34991679Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.J Hematol Oncol2022
35081257Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.Blood Adv2022
34862243Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.Clin Cancer Res2022
34587239t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.Blood Adv2022
34610104Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials.Blood Adv2022
32812370Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.Clin Transl Sci2021
33602684Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.Clin Cancer Res2021
33827116KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.Blood2021
33790022Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.Sci Transl Med2021
33487633Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?Leukemia2021
33621486Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.Cell Stem Cell2021
33586590A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.Leuk Lymphoma2021
  • 1 - 50 of 293

Recommended Authors

Maria Amaya
University of Colorado School of Medicine
Career Start Year 2018
Number of shared co-authors 2
Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 17
Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 28
Jennifer N Saultz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 23
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 26
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Prapti Patel
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 22
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 2
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 6
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 13
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 2
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 36
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 18
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 30
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 21
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 31
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 9
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 37
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Career Start Year 1998
Number of shared co-authors 26
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 36
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 8
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 33
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Career Start Year 1995
Number of shared co-authors 13
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 23
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 33
Meenakshi Devidas
St Jude Children's Research Hospital
Career Start Year 1993
Number of shared co-authors 17
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 9
Sima Jeha
St. Jude Children's Research Hospital
Career Start Year 1988
Number of shared co-authors 16
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 5
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 34

Collaborators

Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 122
Donna Neuberg
Co-authored papers 44
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 37
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 32
Marlise R Luskin
Dana-Farber Cancer Institute
Co-authored papers 31
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 20
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 17
Jorge Cortes
Georgia Cancer Center
Co-authored papers 16
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 15
Robert Coleman Lindsley
Co-authored papers 14
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 13
Jerome Ritz
Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital
Co-authored papers 13
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 13
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 12
Neil P Shah
University of California San Francisco
Co-authored papers 10
Benjamin L Ebert
Co-authored papers 10
Bijal Shah
Moffitt Cancer Center
Co-authored papers 10
Areej El-Jawahri
Harvard Medical School
Co-authored papers 9
Bruno C Medeiros
AbbVie Inc.
Co-authored papers 8
Frank C Kuo
Co-authored papers 8
David M Weinstock
Merck & Co.
Co-authored papers 7
John T Schiller
David Geffen School of Medicine at university of california los angeles
Co-authored papers 7
Alex Look
Dana-Farber Cancer Institute
Co-authored papers 7
Patrick Brown
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 6
Timothy A Graubert
Massachusetts General Hospital
Co-authored papers 6
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 6
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 6
Yana Pikman
Dana Farber Cancer Institute
Co-authored papers 6
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 6
Dong Wook Kim
Yonsei University College of Medicine, Republic of Korea S. Biomedics Co.
Co-authored papers 6
Release 1.2